Your browser doesn't support javascript.
Gender, Bladder Cancer Healthcare and Burden of COVID-19.
Khansary, Shahede; Tavilani, Heidar; Ghasemi, Hadi.
  • Khansary S; Department of Gynecology, Faculty of Medicine, Hamadan university of Medical Sciences, Hamadan, Iran.
  • Tavilani H; Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Ghasemi H; Autophagy Research Center, Department of Biochemistry, School of Medicine, Shiraz University of Medical Science, Shiraz, Iran.
Cancer Invest ; : 1-12, 2022 Nov 02.
Article in English | MEDLINE | ID: covidwho-2231843
ABSTRACT
Bladder cancer as one of the main comorbid diseases might be more susceptible to develop COVID-19 infection with a higher mortality risk during the COVID-19 pandemic. The European Association of Urology (EAU) recommended a comprehensive panel for bladder cancer diagnosis and treatment during this global health problem. The urgent need for treatments of COVID-19 during the pandemic has persuaded researchers to evaluate the different medications, which may lead to drug shortages. Therefore, in this review paper, we have focused on the least recommendations of EAU about bladder cancer during of COVID-19 pandemic to provide a comprehensive panel for high-risk patients.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Journal: Cancer Invest Year: 2022 Document Type: Article Affiliation country: 07357907.2022.2140351

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Journal: Cancer Invest Year: 2022 Document Type: Article Affiliation country: 07357907.2022.2140351